BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
BioRestorative Therapies (NASDAQ:BRTX), a regenerative medicine company specializing in stem cell-based therapies, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is scheduled for October 9, 2024 in New York City.
CEO Lance Alstodt will represent the company at the conference, which will primarily consist of one-on-one investor meetings. Investors attending the conference who wish to meet with BioRestorative are advised to contact their ROTH MKM sales representative to arrange a meeting.
This participation provides an opportunity for BioRestorative to engage directly with investors and showcase its innovative work in stem cell-based therapies and products.
BioRestorative Therapies (NASDAQ:BRTX), un'azienda di medicina rigenerativa specializzata in terapie a base di cellule staminali, ha annunciato la sua partecipazione alla 3a Conferenza Annuale delle Opportunità Sanitarie ROTH. L'evento è programmato per il 9 ottobre 2024 a New York City.
Il CEO Lance Alstodt rappresenterà l'azienda alla conferenza, che consisterà principalmente in incontri individuali con gli investitori. Gli investitori presenti alla conferenza che desiderano incontrare BioRestorative sono invitati a contattare il proprio rappresentante di vendita ROTH MKM per organizzare un incontro.
Questa partecipazione offre a BioRestorative l'opportunità di interagire direttamente con gli investitori e di presentare il suo lavoro innovativo nelle terapie e nei prodotti a base di cellule staminali.
BioRestorative Therapies (NASDAQ:BRTX), una empresa de medicina regenerativa especializada en terapias basadas en células madre, ha anunciado su participación en la 3ª Conferencia Anual de Oportunidades en Salud ROTH. El evento está programado para el 9 de octubre de 2024 en la ciudad de Nueva York.
El CEO Lance Alstodt representará a la empresa en la conferencia, que consistirá principalmente en reuniones individuales con inversores. Los inversores que asistan a la conferencia y deseen reunirse con BioRestorative son aconsejados a contactar a su representante de ventas de ROTH MKM para organizar una reunión.
Esta participación brinda a BioRestorative la oportunidad de interactuar directamente con inversores y mostrar su trabajo innovador en terapias y productos basados en células madre.
BioRestorative Therapies (NASDAQ:BRTX)는 줄기세포 기반 치료를 전문으로 하는 재생 의학 회사로, 제3회 연례 ROTH 의료 기회 컨퍼런스에 참여한다고 발표했습니다. 이 행사에는 2024년 10월 9일 뉴욕시에서 개최될 예정입니다.
CEO Lance Alstodt는 컨퍼런스에서 회사를 대표할 것이며, 주로 개별 투자자 회의로 구성됩니다. 컨퍼런스에 참석한 투자자들 중 BioRestorative와 만나고 싶은 경우, ROTH MKM 판매 담당자에게 연락하여 회의를 일정으로 잡기를 권장합니다.
이번 참여는 BioRestorative가 투자자들과 직접 소통하고 줄기세포 기반 치료와 제품에 대한 혁신적인 작업을 선보일 수 있는 기회를 제공합니다.
BioRestorative Therapies (NASDAQ:BRTX), une entreprise de médecine régénérative spécialisée dans les thérapies basées sur les cellules souches, a annoncé sa participation à la 3e Conférence Annuelle des Opportunités de Santé ROTH. L'événement est prévu pour le 9 octobre 2024 à New York.
Le PDG Lance Alstodt représentera l'entreprise lors de la conférence, qui consistera principalement en réunions individuelles avec des investisseurs. Les investisseurs présents à la conférence qui souhaitent rencontrer BioRestorative sont invités à contacter leur représentant commercial ROTH MKM pour organiser une réunion.
Cette participation offre à BioRestorative l'opportunité d'interagir directement avec les investisseurs et de présenter son travail innovant dans les thérapies et les produits basés sur les cellules souches.
BioRestorative Therapies (NASDAQ:BRTX), ein Unternehmen für regenerative Medizin, das sich auf Therapien mit Stammzellen spezialisiert hat, hat seine Teilnahme an der 3. jährlichen ROTH Healthcare Opportunities Conference bekannt gegeben. Die Veranstaltung ist für den 9. Oktober 2024 in New York City geplant.
CEO Lance Alstodt wird das Unternehmen auf der Konferenz vertreten, die hauptsächlich aus eins zu eins Investorengesprächen bestehen wird. Investoren, die an der Konferenz teilnehmen und BioRestorative treffen möchten, werden gebeten, ihren ROTH MKM Verkaufsvertreter zu kontaktieren, um ein Treffen zu vereinbaren.
Diese Teilnahme bietet BioRestorative die Möglichkeit, direkt mit Investoren zu interagieren und seine innovativen Arbeiten im Bereich der Stammzelltherapien und -produkte vorzustellen.
- None.
- None.
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Executive Officer, Lance Alstodt, will participate in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York City.
The event will consist of a series of one-on-one investor meetings. To arrange a meeting with BioRestorative, attending investors are encouraged to contact their ROTH MKM sales representative.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA) approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ
When and where is BioRestorative Therapies (BRTX) participating in the ROTH Healthcare Opportunities Conference?
Who will represent BioRestorative Therapies (BRTX) at the ROTH Healthcare Opportunities Conference?
What type of meetings will BioRestorative Therapies (BRTX) have at the ROTH Healthcare Opportunities Conference?
How can investors arrange a meeting with BioRestorative Therapies (BRTX) at the ROTH Healthcare Opportunities Conference?
What is the focus of BioRestorative Therapies (BRTX) as a company?
